Abstract:

Objective To study the effect of transcatheter arterial chemoembolization (TACE) combine with 125I implantation in the treatment of primary liver cancer. Method A total of 70 patients with primary liver cancer admitted to Guangzhou RoyalLee Cancer Hospital from October 2022 to August 2023 were selected as the study subjects. They were divided into a control group (TACE treatment) and a study group (TACE combined with 125I implantation treatment) based on a randomized number table method, with 35 patients in each group. The disease remission rate, adverse reaction rate, recurrence rate, and T cell subsets (CD4+, CD8+) and inflammatory factor levels before and after treatment were compared between the two groups. Result Compared with the control group, the remission rate of disease in the study group was higher (91.43%), the recurrence rate was lower (5.71%), the difference was statistically significant (P ＜ 0.05). Before treatment, there was no significant difference in the levels of T cell subsets and inflammatory factors between the two groups (P ＞ 0.05). After treatment, the levels of CD4+ and interleukin-8 in the study group were lower than those in the control group, while the levels of CD8+ and interferon-γ were higher than those in the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion TACE combined with 125I implantation in the treatment of primary liver cancer has significant efficacy, safety, and effectiveness.

Key words: Transcatheter arterial chemoembolization, 125I sead, Primary liver cancer